Eledon Pharmaceuticals (ELDN) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ELDN Stock Alerts $2.02 +0.05 (+2.54%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Resultsfinanznachrichten.de - March 29 at 7:27 AMELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023msn.com - March 29 at 1:22 AMEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Resultsglobenewswire.com - March 28 at 4:01 PMEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejectionglobenewswire.com - March 25 at 4:56 PMEledon Pharmaceuticals’ Tegoprubart Shows Best-in-Class Potential in Organ Transplantationmarkets.businessinsider.com - March 25 at 2:20 AMKidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receivemsn.com - March 21 at 6:48 PMEledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Humanfinance.yahoo.com - March 21 at 6:48 PMEledon Pharmaceuticals, Inc. (ELDN)finance.yahoo.com - February 19 at 7:49 PMEledon Pharmaceuticals Inc ELDNmorningstar.com - February 17 at 2:22 PMEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - February 13 at 7:01 PMEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlookfinanznachrichten.de - January 5 at 9:57 AMEledon Pharmaceuticals reports recent business milestonesmsn.com - January 5 at 9:57 AMEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlookfinance.yahoo.com - January 4 at 6:38 PMWill Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?finance.yahoo.com - December 25 at 7:58 AMEledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conferencefinance.yahoo.com - November 29 at 7:23 PMEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - November 10 at 7:37 AMEledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?msn.com - November 9 at 4:28 PMEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - November 9 at 4:28 PMEledon Pharmaceuticals to Present at Jefferies London Healthcare Conferencefinance.yahoo.com - November 8 at 7:22 PMPromising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant Therapymarkets.businessinsider.com - November 6 at 6:54 PMPromising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami Katkhudamarkets.businessinsider.com - November 4 at 8:55 AMEledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantationfinance.yahoo.com - November 2 at 1:53 PMHC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy Recommendationmsn.com - October 24 at 7:00 PMEledon Pharmaceuticals appoints Eliezer Katz as CMOmsn.com - October 23 at 9:00 AMEledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officermarkets.businessinsider.com - October 23 at 9:00 AMEledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officerfinance.yahoo.com - October 23 at 9:00 AMEledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meetingfinance.yahoo.com - October 13 at 9:59 AMEledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directorsfinance.yahoo.com - October 2 at 8:12 AMNoble Capital Markets Initiates Coverage of Eledon Pharmaceuticals (ELDN) with Outperform Recommendationnasdaq.com - September 28 at 12:26 AMPromising Clinical Trials and Future Projections Bolster Buy Rating for Eledon Pharmaceuticalsmarkets.businessinsider.com - September 27 at 9:24 AMEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Humanfinance.yahoo.com - September 25 at 7:58 AMEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conferencefinance.yahoo.com - September 20 at 8:16 PMEledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primatesfinance.yahoo.com - September 6 at 11:52 AMEledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantationfinance.yahoo.com - September 5 at 11:44 AMCantor Fitzgerald Reiterates Eledon Pharmaceuticals (ELDN) Overweight Recommendationmsn.com - August 22 at 4:40 PMEledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantationfinance.yahoo.com - August 16 at 1:50 PMEledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - August 10 at 8:22 AMIs Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - July 17 at 2:09 PMAmerigo Reports Q2-2023 Production Results and Provides MVC Operational Updatefinance.yahoo.com - July 12 at 8:01 AMSVB Securities Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)markets.businessinsider.com - June 3 at 10:41 AMEledon Pharmaceuticals to Present at Jefferies Healthcare Conferencefinance.yahoo.com - June 2 at 9:25 AMEledon Pharmaceuticals GAAP EPS of -$0.75 misses by $0.11msn.com - May 11 at 7:45 PMEledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - May 11 at 7:45 PMEledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscapemsn.com - May 10 at 6:41 PMEledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023finance.yahoo.com - May 4 at 5:02 PMEledon stock rises ~10% after up to $185M financingmsn.com - May 1 at 10:58 AMEledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trialsfinance.yahoo.com - May 1 at 10:58 AMEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - April 6 at 12:39 AMEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Resultsfinanznachrichten.de - April 1 at 1:56 AMAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN)markets.businessinsider.com - March 31 at 10:52 AM Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << ELDN Media Mentions By Week ELDN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼1.000.38▲Average Medical News Sentiment ELDN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼10▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CLNN News Today MRKR News Today UNCY News Today CARA News Today NRXP News Today PMN News Today OCUP News Today BCTX News Today RMTI News Today BOLT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
